Soleno Therapeutics develops and commercializes treatments for rare diseases, with a focus on Prader-Willi syndrome (PWS) and other rare endocrine disorders. Its lead product, DCCR (Diazoxide Choline Extended Release) tablets, is an oral once-daily medicine designed for its target conditions; the exact biological mechanism is not detailed in the provided information. The company differentiates itself by concentrating on a narrow, underserved niche in biopharma and pursuing regulatory designations like Orphan Drug and FDA Fast Track to help bring treatments to market. Soleno’s goal is to advance its research pipeline and obtain regulatory approval to deliver therapies that can improve outcomes for patients and families affected by rare endocrine disorders.
Company Size
51-200
Company Stage
IPO
Headquarters
Redwood City, California
Founded
1999
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?